Gyre Therapeutics president Ma Songjiang sells $46,280 in stock

Published 13/03/2025, 21:04
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock

Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology company with a market capitalization of $1.02 billion, reported the sale of 4,000 shares of common stock over two days, totaling $46,280. The transactions occurred on March 11 and March 12, 2025, with sale prices ranging from $11.4 to $11.74 per share. These sales were executed under a Rule 10b5-1 trading plan adopted in September 2024. Following these transactions, Ma holds 2,835,260 shares indirectly through a family member. The stock, currently trading at $11.96, has shown strong momentum with a 9% gain over the past week, though InvestingPro analysis suggests the shares are currently overvalued. InvestingPro subscribers have access to 8 additional key insights about GYRE’s valuation and financial health.

In other recent news, Gyre Therapeutics announced the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang, who has a strong financial background, will also serve on the Nominating and Corporate Governance Committee. The company also reported leadership changes at its subsidiary, Gyre Pharmaceuticals, with Songjiang Ma taking over as Chairman following Ying Luo’s resignation to focus on his role at GNI Group Ltd. Gyre Pharmaceuticals is actively advancing its pipeline in China, with ongoing clinical trials for its drug F351 and the commercialization of ETUARY® (Pirfenidone capsule), which achieved net sales of $112.1 million in 2023. The company is also working on treatments for other conditions, including COPD, PAH, and ALF/ACLF. These recent developments reflect Gyre Therapeutics’ strategic focus on expanding its clinical and commercial activities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.